US Market Report for Hemostasis Devices 2017 - MedCore
The value of the total U.S. market for hemostasis devices increased in 2016. Growth is expected to persist throughout the forecasted period and will be driven by increases in unit sales countered by a decrease in the ASP. The vast majority of units in this market are sold to hospitals, with only relatively few units used in the outpatient centers. The four segments have different growth profiles with ligation devices exhibiting low-single digit rate cannibalizing into other segment, and thus resulting in a negative trend within the hemostasis probe segment. The ESU segment remains relatively flat, as this is mainly the replacement market as of 2016. The needle segment is growing at 1% annually as physicians use it as part of the combination therapy. The major contributor to the unit growth in this market is ligation device segment due to high volume coupled with the low-single digit growth rate.
The U.S. market for hemostasis devices is defined in this report as hemostasis probes, ligation devices, sclerotherapy needles and electrosurgical generators. The largest segment in this market was ligation devices. This segment represented approximately 66.1% of the total market in 2016. The relatively large size of this segment is mainly due to these devices being used as both a stand-alone and combination therapy with other devices to address gastrointestinal (GI) bleeding. Also, several units of clips are often used during one procedure. The smallest segment in this market was electro surgical generators (ESUs) due to the longevity of this capital equipment that extends beyond ten years, only one unit required per room, and 100% penetration, all resulting in a lower annual sale volume. Most of the devices discussed in this chapter are single-use, except for reusable heat probes and capital equipment, electro surgical generators including argon modules.